Gamma Therapeutics, Inc.
GT is an early stage biotech start up developing medical devices for cardiovascular disease risk assessment, surgical therapy & hemorrhage control.
GT is a biotech start-up developing medical devices for CVD risk assessment, surgical therapy & hemorrhage control employing human clotting proteins. GT's flagship product, GammaCoeur, is a more predictive CVD test to guide physicians in developing preventive care programs. In 2016, GT won a $225,000 grant from the National Science Foundation to develop a fast-clotting hemorrhage control trauma dressing and is seeking a Phase II, $750 K grant.